Picton Mahoney Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Picton Mahoney Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-134,388	Closed	-$3.4M	–	491
2023 Q2	$3.4M	Buy	134,388 +5,033	+4%	+$157K	0.15%	176
2023 Q1	$4.17M	Buy	129,355 +29,375	+29%	+$916K	0.19%	166
2022 Q4	$1.84M	Buy	99,980 +38,580	+63%	+$882K	0.09%	314
2022 Q3	$1.66M	Buy	+61,400	New	+$1.25M	0.06%	369

Other funds holding RVNC

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Picton Mahoney Asset Management's RVNC Position: Q3 2023 in Review

Picton Mahoney Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2023, closing a stake of 134,388 shares — an estimated $3.4M sold.

Picton Mahoney Asset Management first reported a position in RVNC in Q3 2022 and held it in 4 quarters. The position peaked at $4.17M in Q1 2023. 186 funds tracked by Wall St. Rank hold RVNC as of Q3 2023.

Picton Mahoney Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q3 2023 after selling out during the quarter.
Picton Mahoney Asset Management sold 134,388 Revance Therapeutics, Inc. shares in Q3 2023, an estimated $3.4M.
Picton Mahoney Asset Management first reported a position in Revance Therapeutics, Inc. in Q3 2022 and held it in 4 quarters.
Picton Mahoney Asset Management's Revance Therapeutics, Inc. position peaked at $4.17M in Q1 2023.
186 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2023.

Based on Picton Mahoney Asset Management's 13F filing for Q3 2023, filed 6 Nov 2023.